News & Perspective

Dec 09, 2013

Dec 09, 2013

News Scan for Dec 09, 2013

Mideast polio vaccination
Chikungunya on St. Martin
Meningitis B vaccine
Quadrivalent flu vaccine
Leafy-greens standards
Saudi MERS patients

Oct 06, 2010

Oct 06, 2010

Trial answers some, not all, questions on cell-based flu vaccines

(CIDRAP News) – A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.

Jan 04, 2010

Jan 04, 2010

Three H1N1 vaccine studies confirm safety, weigh dosing

(CIDRAP News) – Large trials in three countries—the United States, Hungary, and China—recently confirmed the safety and efficacy of H1N1 vaccines, yielding new insights on how to best use vaccines in a pandemic setting.

Aug 06, 2009

Aug 06, 2009

WHO says H1N1 vaccine process won't sacrifice safety

(CIDRAP News) – The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.

Jun 16, 2008

Jun 16, 2008

Sanofi to give WHO 60 million doses of H5N1 vaccine

(CIDRAP News) – Sanofi Pasteur pledged today to give 60 million doses of H5N1 influenza vaccine over 3 years to the World Health Organization (WHO) for a planned stockpile to help poor countries in the event of an influenza pandemic.

May 19, 2008

May 19, 2008

EU approves its first prepandemic H5N1 vaccine

(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»